(Total Views: 244)
Posted On: 04/24/2018 11:17:20 AM
Post# of 2022
our first buy recommendation is in and the valuation does not include the canada deal
BREAKING NEWS! EVIO BUY Recommendation issued by Singular Research report issued for small cap fund managers with a target price of 2$
The deal has arrived. The very first independent research report summary of EVIO has now been published!
Quote:
Investment Thesis
*In our view, substantial improvements and ongoing investments in expanded testing service offerings, equipment upgrades and new testing capabilities in existing laboratories should support revenue and earnings growth.
*The expansion in new states via roll out of laboratories particularly California positions the company for sustained future growth.
*With mandatory testing of cannabis products gaining traction, we expect
EVIO to be a significant beneficiary given its wide experience (~50,000 tests conducted so far) and accredited laboratories.
*Cannabis testing is one of the fastest growing subsets in the rapidly growing market of legal medical and recreational marijuana.
*The cannabis testing market is one of the safer investment plays in the
overall cannabis sector which suffers from regulatory overhang.
*The company is poised to grow revenues and earnings over the near to
medium term.
We initiate coverage with a BUY rating and a price target of
$2.00
https://backend.otcmarkets.com/otcapi/company...76/content
Replies:
Nice find. Evio will soon be on everyone’s radar
Scriptohio7 on 4/24/2018 10:41:41 AM
Report TOS
BREAKING NEWS! EVIO BUY Recommendation issued by Singular Research report issued for small cap fund managers with a target price of 2$
The deal has arrived. The very first independent research report summary of EVIO has now been published!
Quote:
Investment Thesis
*In our view, substantial improvements and ongoing investments in expanded testing service offerings, equipment upgrades and new testing capabilities in existing laboratories should support revenue and earnings growth.
*The expansion in new states via roll out of laboratories particularly California positions the company for sustained future growth.
*With mandatory testing of cannabis products gaining traction, we expect
EVIO to be a significant beneficiary given its wide experience (~50,000 tests conducted so far) and accredited laboratories.
*Cannabis testing is one of the fastest growing subsets in the rapidly growing market of legal medical and recreational marijuana.
*The cannabis testing market is one of the safer investment plays in the
overall cannabis sector which suffers from regulatory overhang.
*The company is poised to grow revenues and earnings over the near to
medium term.
We initiate coverage with a BUY rating and a price target of
$2.00
https://backend.otcmarkets.com/otcapi/company...76/content
Replies:
Nice find. Evio will soon be on everyone’s radar
Scriptohio7 on 4/24/2018 10:41:41 AM
Report TOS
(0)
(0)Scroll down for more posts ▼
